US Federal Health Policy: Potential Medicaid Cuts Loom, 340B Program Scrutinized Ahead of Congressional Markup

Washington D.C. – As the United States Congress pauses its legislative work for a brief recess, the federal health policy landscape is bracing for significant potential shifts upon lawmakers’ return. A recent update for the week of April 18-24, 2025, from DeBrunner & Associates highlights critical upcoming legislative actions and regulatory developments that could reshape healthcare access and funding.

The report underscores that both the House of Representatives and the Senate are currently in recess, a pause scheduled to conclude on April 28. However, the quiet period precedes what is anticipated to be a contentious phase, with key committees expected to commence the process of marking up reconciliation legislation by May 9.

Looming Budget Battles and Potential Medicaid Reductions

Central to the upcoming legislative agenda are potential budget cuts that could have profound implications for federal health spending. The Energy and Commerce Committee, a pivotal panel in shaping health policy, is reportedly anticipating marking up its component of the reconciliation bill during the week of May 5. Current projections indicate that this bill could propose total reductions amounting to $880 billion.

A substantial portion of these proposed cuts is expected to target Medicaid, the joint federal and state program providing health coverage to millions of low-income individuals, families, pregnant women, elderly adults, and people with disabilities. The analysis suggests that nearly $550 billion of the anticipated cuts could impact Medicaid spending.

More stories

Healthcare Experts Warn Proposed Medicaid Cuts Could Cripple US Health System, Threaten Rural Hospitals

February 20, 2025

US Obesity Rates: States Achieve First Decline in Over a Decade Amidst Funding Concerns

October 16, 2025

RFK Jr.’s HHS Announces Sweeping Restructure, 20,000 Job Cuts Under Trump Executive Order

March 27, 2025

Federal Health Shake-Up Prompts Alarm, Calls for NJ to Bolster Public Health Safeguards

June 23, 2025

Proposed methods for achieving these significant Medicaid reductions include a range of policy changes. Among the considerations are implementing work requirements for eligibility, which could potentially alter access for certain beneficiaries. Increased enforcement of existing eligibility rules is also on the table. Furthermore, the proposals may involve reducing the federal matching rate (FMAP) specifically for the Medicaid expansion population, a change that would shift a greater financial burden onto states that opted to expand coverage under the Affordable Care Act. Tighter limits on provider taxes and state-directed payments, mechanisms states often use to finance their share of Medicaid costs, are also being examined as potential avenues for achieving savings.

Scrutiny Intensifies on the 340B Drug Pricing Program

Adding another layer of complexity to the federal health policy debate is heightened scrutiny surrounding the 340B Drug Pricing Program. This program requires drug manufacturers to sell outpatient drugs at discounted prices to certain eligible healthcare organizations and pharmacies serving vulnerable communities.

Senator Bill Cassidy (R-LA), who chairs the powerful Senate Health, Education, Labor, and Pensions (HELP) Committee, has recently released a detailed report stemming from an investigation conducted by the committee’s majority staff into the 340B program. The report specifically raises significant concerns regarding whether the program is effectively fulfilling its intended purpose – that of benefiting low-income and uninsured patients.

The HELP Committee’s findings, as detailed in the report, cite studies that suggest the substantial savings generated by the 340B program are not consistently translating into increased care or lower costs for vulnerable patient populations. This finding challenges the core justification for the program’s deep discounts.

In light of these concerns, the report outlines potential program changes that could be considered. These include requiring additional reporting on how participating entities utilize the savings accrued through the 340B program. Increased scrutiny of contract pharmacy arrangements, through which eligible entities dispense 340B drugs via retail pharmacies, is also highlighted as an area needing reform. Furthermore, the report suggests potential legislative adjustments to the definition of an eligible patient and potential changes to the inventory replenishment model currently used by contract pharmacies.

Recent Actions from the Centers for Medicare & Medicaid Services (CMS)

Beyond the legislative sphere, the Centers for Medicare & Medicaid Services (CMS) has continued to issue guidance and take regulatory actions. These include clarifying billing practices for patient transfers to psychiatric units after emergency department visits, addressing a specific payment and coding issue faced by hospitals and providers.

CMS has also taken enforcement action, fining three Program of All-Inclusive Care for the Elderly (PACE) programs for non-compliance with federal regulations. The agency has continued its routine oversight by approving various state plan amendments submitted by states concerning their Medicaid and Children’s Health Insurance Program (CHIP) structures and services.

Additionally, CMS has filed a Paperwork Reduction Act request, seeking to extend the use of Form CMS-460. This form is utilized by Medicare Part B providers to collect information necessary for billing and program administration.

As Congress prepares to return and committees gear up for reconciliation markups, these developments underscore a period of significant potential change and intense debate over the future direction of federal health policy, impacting everything from budget allocations to specific program regulations.